Among numerous reported biochemical effects the lithium-inhibitable enzyme inositolmonophosphatase (IMPase) remains a viable target for lithium's therapeutic mechanism of action.
Introduction
Inositol monophosphatase (IMPase) remains a viable target for the therapeutic effect of lithium as a mood stabilizer (1, 2) . IMPase has an important role in the phosphatidylinositol (PI) signaling system since it catalyzes the dephosphorylation of myo-inositol monophosphates to free myo-inositol (3) . It has been shown that therapeutically-relevant lithium concentrations (0.5-1.5 mM) exert an uncompetitive inhibition on IMPase with a Ki of 0.1 to 1.0 mM, probably by binding to a Mg 2+ -binding site of the enzyme (3) (4) (5) . Reduced activity of IMPase may lead to depletion of intracellular free myo-inositol which is required for the re-synthesis of the signaling precursor PI and thus may dampen overactivity of this signaling cascade (6) . This possibility is known as the inositol depletion hypothesis of the mechanism of lithium's mood stabilizing effect (7): While several studies question the relevance of this hypothesis (8) other results support it (1, 9, 10) .
Based on lithium's inhibition of IMPase activity several pharmaceutical companies have tried to synthesize IMPase inhibitors such as bisphosphonates (11) and terpenoid and tropolone analogues (12) targeted at the substrate site of the enzyme. However, their further development to clinical mood stabilizers was limited for a variety of reasons (11) .
Calbindin D 28 k (calbindin), a member of the vitamin-D-dependent calcium-binding proteins, was found to activate IMPase in vitro (13) . It was shown that calbindin binds a specific amino-acid sequence of IMPase (residues 55-66) enhancing its activity by several fold (13) . Calbindin is common in neurons of the hippocampus (14) , temporal cortex (15) , anterior cingulate cortex (16) and prefrontal cortex (17) constituting about 1% of total brain soluble protein (18) . Calbindin shapes postsynaptic calcium signals (19) (20) (21) , and is involved in synaptic plasticity (22) . Schmidt et al (21) have shown in situ that calbindin's interaction with IMPase occurs in spines and dendrites but not in axons of cerebellar Purkinje neurons which depend on PI signaling for synaptic integration. The interaction is enhanced by synaptic activity and results in calbindin's immobilization by membrane-or cytoskeleton-bound IMPase (21) . We have previously shown that addition of recombinant human calbindin increases IMPase activity of postmortem human prefrontal cortex crude homogenate by 3.5 fold (23) . Given the fact that calbindin is highly abundant in brain tissue it is conceivable to assume that in-vivo, brain IMPase is constitutively bound to calbindin and that this protein-protein interaction is involved in PI-mediated synapse function.
In the present study we explored the possibility to inhibit IMPase activity at the calbindin-IMPase interaction site using competitive peptides which would interfere with the activating interaction. Four six amino-acid linear peptides rationally designed based on in silico modeling of the interaction inhibited calbindin-activated brain IMPase activity in vitro. One of these peptides was tested in vivo in an animal model of depression, the Porsolt forced swim test (FST), and exhibited an antidepressant-like reduced immobility. Based on the backbone of this linear peptide, cyclic and linear pre-cyclic analog peptides were synthesized to potentially increase the peptide's stability. One cyclic peptide and one linear pre-cyclic peptide exhibited an inhibitory effect on calbindin-enhanced brain IMPase activity in vitro. These findings may lead to the development of molecules capable of inhibiting IMPase activity at an alternative site than that of lithium.
Materials and Methods
Modeling the structure of the complex between IMPase and calbindin Figure 1 , showing the three dimensional structure of IMPase and of the complex of IMPase with calbindin, was produced using the program PyMol (24) . The crystal structure of IMPase (PDB entry 2bji) and the NMR structure of calbindin (PDB entry 2g9b) were used to model the structure of the complex using the protein-protein docking program MolFit (25) . For a full and detailed description of the modeling process please refer to the Supplementary Information.
Peptides design based on the modeled complex
We used the resulting model as a basis for designing eleven short linear peptides (Table 1) . Peptide 1, a 6-mer peptide, was composed of an identical sequence as residues 58-63 of IMPase (Ile-Lys-GluLys-Tyr-Pro). These six amino acids are the central sequence of the previously reported 12 amino acid segment (residues 55-66) of IMPase shown to interact with calbindin (18) . Furthermore, this specific 6-mer peptide is fully conserved between mouse and human. This segment includes Lys59 and Lys61, separated by Glu60 designated the Lys-Glu-Lys motif. Additional designed three 6-mer peptides included at least part of the Lys-Glu-Lys motif (peptides 2-4). In peptide 2 we permutated Glu60 to alanine. Peptides 3 and 4 are similar to peptide 1 but in each peptide one of the Lys residues in the LysGlu-Lys motif was permutated to alanine. Four other 6-mer peptides included only one or none of the amino acids Lys or Glu of the Lys-Glu-Lys motif (peptides [5] [6] [7] [8] . In peptide 5 one of the lysine residues and Ile58 were permutated to histidine and serine, respectively, and the whole sequence has been scrambled. Peptide 6 was composed of the same sequence as peptide 1 but the two lysine residues were permutated into alanine. Peptide 7 was also composed of the same sequence as peptide 1 but the whole Lys-Glu-Lys motif has been permutated to three alanine residues (Ala-Ala-Ala). Peptide 8 was a random 6-mer peptide containing two lysine residues, albeit, separated by two, rather than a single residue, none of which was a glutamate. Two 5-mer peptides lacking the carboxyterminal proline included either the Lys-Glu-Lys motif (peptide 9) or Lys-Ala-Lys replacement (peptide 10). One 3-mer peptide was composed of the Lys-Glu-Lys motif only (peptide 11). The peptides were customsynthesized by GeneScript Corporation, Scotch Plains, NJ (Table 1) .
Mutated calbindin
Human recombinant calbindin was mutated at the Israel Structural Proteomics Center (ISPC), the Weizmann Institute of Science (Rehovot, Israel) to exchange residues Asp24 and Asp26 into alanine (calbindin D24A, D26A). Calbindin D24A, D26A was generated by site-directed mutagenesis based on the QuikChange site-directed mutagenesis protocol of Stratagene (La Jolla, CA). For a full and detailed description of the preparation of mutated calbindin please refer to the Supplementary Information.
IMPase activity
IMPase activity in mouse brain homogenates was measured as previously described (26) . Inorganic phosphate liberated from inositol-1-phosphate was quantified spectrophotometrically in an ELISA reader (iEMS, Labsystems, Helsinki, Finland) using the malachite green color reagent. To study the effect of the synthetic peptides on the enhancing interaction between calbindin and IMPase the reaction was carried out in the presence of 20 μM human recombinant calbindin (27) (produced by PPS, Rehovot, Israel, using the plasmid kindly donated by S. Linse, Lund, Sweden) and in the presence or absence of 10 μM of each of the peptides. In order to distinguish IMPase activity from non-specific phosphatases the reaction was carried out in the presence and absence of 30 mM LiCl. LiCl is a specific inhibitor of this enzyme (3) 
Effect of specific peptides in the Porsolt forced swim test
Eight weeks old ICR male mice (Harlan, Jerusalem, Israel) were anesthetized with 20% isoflurane and a screw guide was implanted 0.2-0.3 mm posterior to the bregma 1 mm lateral to midline, above the lateral ventricle. The incision was closed and the mice were put back in their cage with 5% lidocaine administered locally and 1.25 g dipyrone/200 ml in the drinking water was given for analgesia. After a week of recovery, mice were anesthetized and injected through the guide screw with 5 µl of liposomes containing the test peptide (peptide 1 IKEKYP: 50 nmoles, n=13, peptide 5 SYEHKP: 50 nmoles, n=5) or aCSF as control (n=8). Three hours later mice were placed for 6 minutes in a glass cylinder (height 20 cm, diameter 12 cm) filled with water at a temperature of 24 ± 1ºC to a height of 13 cm (such that the mouse could not touch the bottom or climb out of the cylinder at any point). The session was digitally recorded for later analysis. Analysis of the digitally recorded behavior was done by an experimenter who was blind to a mouse treatment. The duration of immobility was monitored during the last 4 min of the 6-min test. Immobility period was defined as the time spent by the animal floating without struggling and making only those movements necessary to keep its head above the water. In addition, another group of mice received a single i.p. injection of 15 mg⁄kg imipramine hydrochloride (Sigma, St. Louis, MO) 30 min before the test and were used as a positive control of an antidepressant effect. After the test the screw location was confirmed by dye injection.
Synthesis and measurement of metabolic stability of cyclic and linear pre-cyclic analog peptides
Synthesis of cyclic and linear pre-cyclic analog peptides was based on the concept of backbone cyclization (28, 29) . The metabolic stability of cyclic peptide 1 was measured using rat brush border membrane vesicles as previously described (30) . For a full and detailed description of these methodologies please refer to the Supplementary Information.
Results
A modeled structure of the complex between IMPase and calbindin suggests that residues Lys59,
Glu60 and Lys 61 of IMPase play a major role in the interaction
A plausible model of the interaction between IMPase and calbindin was obtained using the docking program MolFit followed by energy minimization. Residues 55-66 of IMPase comprise the segment which has been shown to interact with calbindin (13) . In the docking procedure residues 55-66 of IMPase were placed in the interface between the two proteins. In contrast, no restraints were imposed on the interacting surface of calbindin. In the modeled complex depicted in Figure 1 
Specific linear peptides inhibit calbindin-activated IMPase
The effect of specifically designed linear peptides was validated by in vitro IMPase activity measurements in the presence of calbindin. As shown in Figure 2 IMPase activity of mouse brain crude homogenate is increased by 1.9 ± 1.0 (S.E.M.) fold in the presence of 20 μM human recombinant calbindin. When 10 μM of peptide 1 were added to the reaction mixture the effect of calbindin on IMPase activity was strongly reduced. Peptides 2 through 4, which included the Lys-Glu-Lys motif or part of it, inhibited the activating interaction similarly to peptide 1 (Figure 2A Figure 2B ). Peptides 9 and 10, comprised of five amino acids and peptide 11 comprised of three amino acids which contained either an intact Lys-Glu-Lys motif or a LysAla-Lys replacement did not interfere with the enhancement of IMPase activity by calbindin ( Figure   2C ). Our results suggest that peptides 1 through 4 but not peptides 5 through 11 contain the preferred residues that optimize the competition with IMPase on the interaction with calbindin.
The inhibitory effect of peptide 1 on calbindin-activated IMPase was also demonstrated with postmortem human brain crude homogenate. Human recombinant calbindin increased human brain IMPase activity by 3 fold and peptide 1 abolished this effect (data not shown).
To control for a possible nonspecific effect of linear short peptides on IMPase activity the enzyme's activity in the presence of peptide 1 (but in the absence of calbindin) was assessed. Peptide 1 did not affect the basal activity of IMPase. We further assessed possible protease activity in the homogenate and the possibility that prior interaction between IMPase and calbindin prevents interference by the active peptides. To this end we preincubated calbindin with the homogenate for 10 min prior to the addition of the substrate. No difference in IMPase activity was found in these two experiments (data not shown).
IMPase activity in mouse brain crude homogenate is not enhanced by mutated human recombinant calbindin
We examined whether a change in the interaction site of calbindin with IMPase will affect calbindin's activation of IMPase. Human recombinant calbindin was mutated so that two amino acids in its interaction site with IMPase, Asp24 and Asp26, were replaced by alanine. IMPase activity in mouse brain crude homogenate was measured in the presence of 20 μM mutated vs. wildtype calbindin. As shown in Figure 3 , differently from wildtype calbindin, IMPase activity was not enhanced by 20 μM mutated calbindin [ANOVA F 2, 14 = 21.8, p<0.001; post-hoc analysis: the activity in the presence of wildtype calbindin was significantly different from both the control (p<0.001) and the activity in the presence of mutated calbindin (p<0.001)].
Specific cyclic and linear pre-cyclic analog peptides inhibit calbindin-activated IMPase
Out of the two cyclic and two linear pre-cyclic analog peptides (Table 1) 
Enhanced metabolic stability of cyclic peptide 1
Comparison of the stability of cyclic peptide 1 with that of linear peptide 1 revealed that cyclic peptide 1 maintained 50% of its initial amount after 60 minutes of incubation with BBMVs while its linear analog was completely degraded after 5 minutes. The enhanced stability contributed by cyclization adds "drug like" properties required for further development for potential clinical utilization (30) . 
Peptide 1 but not peptide 5 exhibited an in-vivo antidepressant-like effect in the FST

Discussion
IMPase, a critical enzyme for brain cell signaling (26: Atack, 1995 #624, 31) , is activated by calbindin (13), a ubiquitous protein (32) (33) (34) constituting about 1% of brain protein content (35) .
Lithium, a mainstay treatment in bipolar disorder, inhibits IMPase at therapeutically-relevant concentrations. This inhibition is among the hypotheses of the molecular mechanism of lithium's therapeutic action (7) . Since lithium has significant limitations and since repeated efforts by several drug companies to develop alternative IMPase inhibitors directed to the catalytic site of the enzyme were non-successful (11, 12, 31) we studied the possibility to inhibit IMPase activity by targeting another site, namely, the site through which it is being activated by calbindin. This was based on the assumption that in-vivo, in neurons of particular brain sub-regions (36) implicated to be involved in mood regulation (16, 17) and where calbindin is abundant, calbindin's interaction with IMPase enhances the enzyme activity.
Interfering with protein-protein interaction is a new paradigm in drug discovery for neurological and psychiatric disorders (37, 38) . Small molecule inhibitors designed within this concept include short peptides (39) . To rationally design short peptides as potential competitive inhibitors of calbindinactivated IMPase we modeled in silico the structure of the IMPase-calbindin complex by docking the NMR structure of calbindin (40) to the crystal structure of bovine IMPase (41) . The model suggested that out of the 12 amino acid segment of IMPase which interacts with calbindin (residues 55-66) (13) two IMPase residues, Lys59 and Lys61, are hydrogen bonded to calbindin. The residue in between these two lysine residues, Glu70, also participates in the interaction with calbindin. The two lysine residues interacting with two aspartate residues of calbindin (Asp24 and Asp26) are among the central six amino acids of the 12 amino acid segment which is conserved between human and mouse IMPase.
We experimentally assessed the role of the Lys-Glu-Lys motif of IMPase and the role of Asp24 and Asp26 of calbindin in the interaction between the two proteins by assessing the inhibitory effect of different peptides on the enhancement of mouse brain crude homogenate IMPase activity by wildtype or mutated human recombinant calbindin. The inhibitory effect of the linear peptides 2 through 4 ( Table 1) on calbindin's activation of IMPase was comparable to that of the 6-mer peptide composed of an identical sequence as residues 58-63 of IMPase (peptide 1; Table 1 ) as long as the permutated peptide included the Lys-Glu-Lys motif, or at least a part of it. Nonetheless, five amino acid peptides which included a Lys-X-Lys motif but lacked the C-terminal proline residue (peptides 9 and 10; Table 1 ) did not inhibit the activation of IMPase by calbindin indicating a requirement for this specific carboxyl terminal residue. A three amino acid peptide comprised of the Lys-Glu-Lys motif only (peptide 11; Table 1 ) also did not inhibit IMPase activation by calbindin. This result suggests that the Lys-Glu-Lys motif, or part of it, is necessary but not sufficient for the peptide to inhibit calbindin's activation of IMPase and defines a size constraint of at least six amino acids required to inhibit the activation of IMPase by calbindin. A similar result of gradual decreased length of an inhibitory peptide affecting its potency was observed for peptides inhibiting polyglutamine protein aggregation and cell death in neurodegenerative diseases including Huntington's disease (42) . To further evaluate the validity of our in silico model we assessed the role of calbindin's Asp24 and Asp26 residues in the interaction with IMPase using a mutated calbindin in which both of these aspartate residues were mutated into alanine.
Unlike wildtype calbindin the mutated calbindin did not activate IMPase. This result supports the model's implication that these two aspartate residues of calbindin play a significant role in the interaction of the protein with IMPase. (Table 1) on the forced swim test in mice. We hypothesized that similarly to lithium peptide 1 but not peptide 5 will exhibit an antidepressant-like reduction of immobility (43, 44) . Our results confirmed our hypothesis and provided an in vivo behavioral proof of concept for the novel site through which it may become possible to design novel mood stabilizers.
The use of peptides as drugs endures both advantages and disadvantages. Although peptides are highly selective, can be synthetically produced and optimized, in vivo they exhibit short half-lives, poor bioavailability and decreased cell permeability, limiting their use in the clinics (45, 46) . This may be due to lack of solubility, rapid enzymatic degradation by the intestinal proteolytic enzymes or poor intestinal permeability. Different pharmaceutical and chemical approaches were developed to enhance oral bioavailability of peptides while maintaining their pharmacological activity. Peptide cyclization or blocking their N-and C-terminal amino acids has been shown to address these limitations rendering the peptides to exhibit increased potency, increased stability to proteolytic degradation and enable their binding to the target at decreased effective concentrations (47, 48) . In the present study the cycloscan and backbone cyclization methods (29, 30, 49) were used to circumvent the problems that hamper the conversion of peptides into drugs. Utilizing cyclic or linear pre-cyclic analog peptides in which the pharmacophors are preserved in the same sequence and constitution as in the parent peptide 1 we were able to mimic peptide 1's inhibitory effect on the activation of IMPase by calbindin in vitro. The enhanced stability of cyclic peptide 1 compared with it's linear analog adds "drug like" property required for further development for potential clinical utilization (30) .
Obviously, further studies should investigate whether cyclic or linear pre-cyclic peptides modified to exhibit membrane permeability and biological stability (48) , or nonpeptide small molecules (38) based on our in silico model, can mimic behavioral effects of lithium in inositol-related paradigms (50, 51) or other lithium-induced behavioral effects in animals (52). The figure was produced using the program PyMol. A. The effect of six amino acid linear peptides containing the Lys-Glu-Lys motif or part of it (see Table 1 B. The effect of six amino acid linear peptides which include only one or none of the amino acids Lys or Glu of the Lys-Glu-Lys motif compared to peptide 1 (see Table 1) ANOVA: F(6, 55)=1.8, p=0.11 Post hoc LSD test: * control vs. calbindin, p=0.01 ** calbindin vs. peptide 1, p=0.007
C. The effect of two five amino acid peptides (peptides 9 and 10) and a three amino acid peptide containing the Lys-Glu-Lys motif or a Lys-Ala-Lys replacement compared with peptide 1 (see 
